1367TiP IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Year: 2021
Type: article
Source: Annals of Oncology
Authors: R. Laeufle, G. Richardson, J.J.W. Park, M. Gutierrez, M. Boyer, D. Carbone, P. Savvides, T. Bekaii-Saab, P. Kaumaya, T. Phan, N. Ede, L. Chong, B. Nixon, A. Good
Institutions: Cabrini Hospital, Macquarie University, Hackensack University Medical Center, Chris O’Brien Lifehouse, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Garvan Institute of Medical Research
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3202438128